EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy

Lei Wang iD, Yufeng Xiao iD, Yuewan Luo iD, Rohan P Master iD, Jiao Mo iD, Myung-Chul Kim iD, Yi Liu iD, Chandra K Maharjan iD, Urvi M Patel iD, Umasankar De iD, Madison E Carelock iD, Tanzia Islam Tithi iD und 10 weitere

Journal of Experimental Medicine · 04.03.2024 · 221 (3)

DOI: 10.1084/jem.20231519 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 09.02.2024. Verfasst von Lei Wang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Melanoma, Myeloid-Derived Suppressor Cells. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An effective cancer therapy requires killing cancer cells and targeting the tumor microenvironment (TME). Searching for molecules critical for multiple cell types in the TME, we identified NR4A1 as one such molecule that can maintain the immune suppressive TME. Here, we establish NR4A1 as a valid target for cancer immunotherapy and describe a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades NR4A1 within hours in vitro and exhibits long-lasting NR4A1 degradation in tumors with an excellent safety profile. NR-V04 inhibits and frequently eradicates established tumors. At the mechanistic level, NR-V04 induces the tumor-infiltrating (TI) B cells and effector memory CD8+ T (Tem) cells and reduces monocytic myeloid-derived suppressor cells (m-MDSC), all of which are known to be clinically relevant immune cell populations in human melanomas. Overall, NR-V04–mediated NR4A1 degradation holds promise for enhancing anticancer immune responses and offers a new avenue for treating various types of cancers such as melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaMyeloid-Derived Suppressor CellsHumansCell Line, TumorImmunotherapyNuclear Receptor Subfamily 4, Group A, Member 1Tumor MicroenvironmentProteolysis Targeting Chimera

Substanzen

NR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Proteolysis Targeting Chimera

Autor:innen und Institutionen

  • Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA.
  • Veterinary Diagnostic Laboratory Medicine, College of Veterinary Medicine, Jeju National University, Jeju-si, South Korea.
  • Sanofi Oncology, Sanofi , Cambridge, MA, USA.
  • Sanofi Integrated Drug Discovery, Sanofi , Cambridge, MA, USA.
  • Rheumatology and Clinical Immunology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

ORCID-Profile: Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung-Chul Kim, Yi Liu, Chandra K Maharjan, Urvi M Patel, Umasankar De, Madison E Carelock, Tanzia Islam Tithi, Xiangming Li, Donald R Shaffer, Kevin R Guertin, Haoyang Zhuang, Emily Moser, Keiran S M Smalley, Dongwen Lv, Daohong Zhou, Guangrong Zheng, Weizhou Zhang

Förderung

  • NIH HHS
  • NCI NIH HHS
  • U.S. Department of Defense
  • Congressionally Directed Medical Research Programs
  • Sanofi
  • National Institutes of Health
  • Dr. and Mrs. James Robert Spenser Family

Zitieren

APA

Wang, L., Xiao, Y., Luo, Y., Master, R. P., Mo, J., Kim, M. C., Liu, Y., Maharjan, C. K., Patel, U. M., De, U., Carelock, M. E., Tithi, T. I., Li, X., Shaffer, D. R., Guertin, K. R., Zhuang, H., Moser, E., Smalley, K. S. M., Lv, D., …, & Zhang, W. (2024). PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. Journal of Experimental Medicine, 221(3). https://doi.org/10.1084/jem.20231519

Vancouver

Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. Journal of Experimental Medicine. 2024;221(3). doi:10.1084/jem.20231519

BibTeX
@article{Wang2024,
  author = {Wang, Lei and Xiao, Yufeng and Luo, Yuewan and Master, Rohan P and Mo, Jiao and Kim, Myung-Chul and Liu, Yi and Maharjan, Chandra K and Patel, Urvi M and De, Umasankar and Carelock, Madison E and Tithi, Tanzia Islam and Li, Xiangming and Shaffer, Donald R and Guertin, Kevin R and Zhuang, Haoyang and Moser, Emily and Smalley, Keiran S M and Lv, Dongwen and Zhou, Daohong and Zheng, Guangrong and Zhang, Weizhou},
  title = {PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  volume = {221},
  number = {3},
  doi = {10.1084/jem.20231519}
}
Kostenlos starten →